OYST Oyster Point Pharma Inc.

FDA Catalyst Company
3.91
-0.08  -2%
Previous Close 3.99
Open 3.99
52 Week Low 3.76
52 Week High 21.01
Market Cap $104,277,127
Shares 26,669,342
Float 14,006,460
Enterprise Value $56,401,674
Volume 57,543
Av. Daily Volume 129,179
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/09/2021

Latest News

    • TYRVAYA® Nasal Spray Net Product Revenue of $2.7 Million in Q1'22
    • Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals
    • Expansion of Commercial Coverage for TYRVAYA, with Up to Approximately 95 Million Lives Covered to Date
    • Licensing Partner, Ji Xing Pharmaceuticals, Authorized to Conduct Phase 3 Clinical Trial of OC-01 in China
    • Continuing Enrollment of Subjects in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopathy, with Study Results Expected in 2H 2022
    • Additional Pre-Clinical Studies Underway for Enriched Tear Film Gene Therapy to Target Stages 2 and 3 Neurotrophic Keratopathy
    • Conference Call and Webcast Scheduled for 4:30 pm ET Today

    PRINCETON…

    View Full Article
  1. PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the market close. The announcement will be followed by a live audio webcast and conference call at 4:30 p.m. Eastern Time.

    Conference Call Details
    To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International). The conference ID number is 4149318. A telephone replay will be available for approximately 7 days following the live conference…

    View Full Article
  2. PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4.

    "We are pleased to be presenting new analyses of the pivotal trial data of TYRVAYA® (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease at ARVO, the premiere gathering for eye and vision scientists to share the latest research findings and collaborate on innovative solutions," said Marian…

    View Full Article
  3. PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of data analyses at the American Society of Cataract and Refractive Surgery (ASCRS), being held on April 22-26.

    "The data we're presenting at ASCRS, the largest meeting of anterior segment surgeons, underscores Oyster Point Pharma's commitment to improving the care for people suffering with dry eye disease, a chronic condition that impacts an estimated 38 million people in the U.S.," said Marian Macsai, MD chief medical officer, Oyster…

    View Full Article
  4. PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that William J. Link, Ph.D., is retiring from Oyster Point's Board of Directors, effective as of March 17, 2022. Dr. Link will continue to serve as a consultant to the company.

    "On behalf of the entire Oyster Point organization, we are eternally thankful to Dr. Link for his leadership and significant contributions over the years," said Jeffrey Nau, M.M.S, Ph.D., president and chief executive officer, Oyster Point Pharma. "Even in his retirement, he will…

    View Full Article
View All Oyster Point Pharma Inc. News